CUG252 advances to Phase1b studies for patients with mild-to-moderate Systemic Lupus Erythematosus (SLE). The trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of this novel treatment, and aiming to assess its efficacy and determine its potential for broader clinical application.